{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-087269","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2026-07-28T10:05:27+00:00","discovered_at":"2026-07-28T10:10:00.263852+00:00","generated_at":"2026-07-28T10:10:03.841172+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ProMIS reports positive blinded 6-month interim data for PMN310 in Alzheimer's Phase 1b trial","bullets":["No ARIA-E observed across all genotypes; 4.4% total ARIA (all mild, asymptomatic ARIA-H) with no drug-related discontinuations.","61% of patients were APOE4 carriers (11% homozygotes); no ARIA-E in any genotype, including this high-risk group.","68.5% of patients had decline in plasma pTau217; 62.5% had decline in CSF MTBR-tau243, consistent with target engagement.","Trial remains blinded; unblinded 12-month topline efficacy data expected in Q1 2027.","PMN310 designed to selectively bind toxic amyloid-beta oligomers while avoiding plaque, aiming to decouple efficacy from ARIA risk."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-087269","json":"https://secwatch.observer/filing/0001104659-26-087269.json","markdown":"https://secwatch.observer/filing/0001104659-26-087269.md","text":"https://secwatch.observer/filing/0001104659-26-087269.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926087269/0001104659-26-087269-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926087269/pmn-20260728x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-28T10:10:03.841172+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}